Youssef Hijazi
Sanofi R&D, Sanofi
Frankfurt Am Main, HE, Germany
Frankfurt Am Main, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa.
Journal: The journal of allergy and clinical immunology. Global
Published: June 13, 2024
Utility of in silico prediction of target suppression for antibodies against soluble targets: static versus dynamic models.
Journal: European journal of clinical pharmacology
Published: July 15, 2022
Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges.
Journal: European journal of drug metabolism and pharmacokinetics
Published: November 13, 2020
Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.
Journal: Current clinical pharmacology
Published: March 28, 2018
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Journal: Diabetes, obesity & metabolism
Published: February 07, 2018
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.
Journal: Experimental hematology & oncology
Published: March 29, 2017
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 05, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026